NCT05924620View on ClinicalTrials.gov

Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 21, 2023

Primary Completion Date

March 12, 2024

Study Completion Date

March 12, 2024

Conditions
Primary Aldosteronism
Interventions
DRUG

finerenone

Patients with PA divided into Intervention group need to take finerenone for 60 days (20mg qd).

Trial Locations (1)

400016

The First Affilated Hospital of Chongqing Medical University, Chongqing

All Listed Sponsors
lead

Chongqing Medical University

OTHER